← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Riparian Pharmaceuticals, Inc.
Watertown, MA
$3,663,318
Total funding
3
Grants
Funding over time
peak $1.2M · FY2013–23$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,663,318 · 3
By mechanism
R44$2,804,643 · 1
R41$541,432 · 1
R43$317,243 · 1
Investigators at Riparian Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$1,229,878
R44 · FY2017 · HL
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$857,294
R44 · FY2016 · HL
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$697,873
R44 · FY2018 · HL
Pharmacological induction of KLF2 and reversal of endothelial dysfunction for the treatment of hypertension$310,743
R43 · FY2022 · HL
Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis$292,909
R41 · FY2014 · HL
Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis$245,125
R41 · FY2013 · HL
Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis$19,598
R44 · FY2017 · HL
Pharmacological induction of KLF2 and reversal of endothelial dysfunction for the treatment of hypertension$6,500
R43 · FY2023 · HL
Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis$3,398
R41 · FY2014 · HL